NCT01485835View on ClinicalTrials.gov

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Ganetespib

Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.

DRUG

Bortezomib

Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.

DRUG

Dexamethasone

Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.

Trial Locations (8)

22031

Virginia Cancer Specialists, Fairfax

28204

Levine Cancer Institute, Charlotte

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Winship Cancer Institute, Atlanta

48201

Barbara Ann Karmanos Cancer Institute, Detroit

63110

Siteman Cancer Center at Washington University, St Louis

76104

The Center for Cancer and Blood Disorders, Fort Worth

80218

Colorado Blood Cancer Institute, Denver

All Listed Sponsors
collaborator

Multiple Myeloma Research Consortium

NETWORK

collaborator

Synta Pharmaceuticals Corp.

INDUSTRY

lead

Emory University

OTHER

NCT01485835 - A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter